Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction
Lars Michel1, Peter Ferdinandy2,3, Tienush Rassaf4
1Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany. Lars.Michel@uk-essen.de.
Current Heart Failure Reports
|March 2, 2024
Summary
Immune checkpoint inhibitor (ICI) therapy can cause significant cardiovascular toxicity. Understanding these mechanisms is crucial for developing cardioprotective strategies in cancer patients.
Area of Science:
- Cardio-oncology
- Immunology
- Cardiovascular Medicine
Background:
- Immune checkpoint inhibitor (ICI) therapy is a vital cancer treatment.
- ICI therapy is increasingly associated with significant cardiovascular toxicity.
- The role of immune checkpoints in cardiac health is under active investigation.
Purpose of the Study:
- To elucidate the mechanisms of ICI-related cardiovascular complications.
- To review preclinical and mechanistic data on ICI cardiotoxicity.
- To highlight recent findings and future directions in cardio-oncology.
Main Methods:
- Literature review focusing on preclinical and mechanistic studies.
- Analysis of emerging scientific data on ICI cardiotoxicity.
- Synthesis of current understanding and hypothesis generation.
Main Results:
- Immune checkpoints play a critical role in maintaining cardiac integrity.
- New data reveal previously unrecognized forms of cardiotoxicity associated with ICIs.
- Understanding ICI effects is key to identifying at-risk patients.
Conclusions:
- Cardiotoxicity from ICI therapy presents a major challenge in cardio-oncology.
- Elucidating underlying mechanisms is essential for developing tailored cardioprotective strategies.
- Further research can leverage ICI knowledge for novel therapeutic approaches.
Keywords:
Cardio-oncologyCardiotoxicityHidden cardiotoxicityImmune checkpoint inhibitorImmune-related adverse eventsProgrammed cell death protein 1More Related Videos
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
11.7K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:26Heart Failure Drugs: Inotropic Agents
586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524